Cytochrome P450 3A Inhibitor class drugs

4 results

  • evotaz

    (atazanavir and cobicistat)
    E.R. Squibb & Sons, L.L.C.
    EVOTAZ® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for adults and pediatric patients weighing at least 35 kg. Its use in treatment-experienced patients should be guided by baseline protease inhibitor resistance.
    Medication Details
    Drug Interactions

  • genvoya

    (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide)
    Gilead Sciences, Inc.
    GENVOYA is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥25 kg) with no prior antiretroviral treatment history or to replace an existing regimen in virologically-suppressed patients on a stable regimen for at least six months without treatment failures or resistance.
    Medication Details
    Drug Interactions

  • stribild

    (elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate)
    Gilead Sciences, Inc.
    STRIBILD® is indicated for treating HIV-1 in adults and pediatric patients aged 12 and older (weighing at least 35 kg) without prior antiretroviral treatment or to replace a stable regimen in those virologically suppressed for at least 6 months, without resistance to its components.
    Medication Details
    Drug Interactions